Adelba Torres-Lopez, MD
Hematology & Oncology · San Juan, PRNPI 1063826543
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (35.8%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by ADC Therapeutics America, Inc. at 41.1% of the total. 2025 is the largest year on record at $30,006, more than ten times the $1,832 reported in 2019. Among hematology & oncology clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 932 payments — averaging $78.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ADC Therapeutics America, Inc.$30K
- Genentech USA, Inc.$13K
- E.r. Squibb & Sons, L.L.C.$7K
- Merck$6K
- AbbVie$2K
- Johnson & Johnson$2K
- plus $13K from 54 others
Across 203 payments — averaging $8868.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$691K
- Beigene, Ltd.$345K
- Beone Medicines Ltd.$317K
- Janssen Research & Development, LLC$93K
- Genentech, Inc.$62K
- Pfizer$59K
- plus $233K from 10 others
What the payments were for
- Consulting fees$15,59921%
- Speaking & faculty fees$26,04036%
- Travel & lodging$9,35513%
- Food & beverage$20,87029%
- Education$9681%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$72,833 in reported general payments places this provider in the 90th percentile of 138 hematology & oncology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 36 | $569,698 |
| IbrancePalbociclib | 18 | $288,982 |
| XtandiEnzalutamide | 11 | $159,400 |
| SprycelDasatinib | 14 | $151,822 |
| VenclextaVenetoclax | 14 | $110,125 |
| PromactaEltrombopag Olamine | 13 | $91,328 |
| FulphilaPegfilgrastim-Jmdb | 15 | $33,708 |
| Imatinib Mesylate | 13 | $10,348 |
| Anastrozole | 283 | $5,322 |
| Tamoxifen Citrate | 57 | $1,775 |
| SynthroidLevothyroxine Sodium | 21 | $1,364 |
| Dexamethasone | 24 | $734 |
| Exemestane | 16 | $721 |
| Ondansetron Hcl | 34 | $573 |
| Letrozole | 30 | $551 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCVerzenio | $327 | $569,69836 claims |
| PfizerIbrance | $314 | $288,98218 claims |
| Astellas Pharma US IncXtandi | $500 | $159,40011 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $6,609 | $151,82214 claims |
| AbbVieVenclexta, Synthroid | $2,382 | $111,48935 claims |
| NovartisPromacta | $1,053 | $91,32813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 138 hematology & oncology providers in Puerto Rico.
Other hematology & oncology in San Juan
- Alexis Cruz ChaconSan Juan$450K
- Jose Lozada CostasSan Juan$260K
- Cristian Rodriguez ArochoSan Juan$227K
- Noridza Rivera RodriguezSan Juan$177K
- Mirelis AcostaSan Juan$154K
- Luis Baez VallecilloSan Juan$107K
- Edgardo Santiago-GuzmanSan Juan$79K
- Karla Feliciano SalvaSan Juan$44K
- Luis Delgado MateuSan Juan$39K
- Sixto PerezSan Juan$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.